# Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

> **NCT05760586** · — · APPROVED_FOR_MARKETING · sponsor: **Day One Biopharmaceuticals, Inc.**

## Conditions studied

- Low-grade Glioma

## Interventions

- **DRUG:** Tovorafenib

## Key facts

- **NCT ID:** NCT05760586
- **Lead sponsor:** Day One Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05760586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05760586, "Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05760586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*